Company: HRTX
Filing Date: 2025-05-06
Form Type: S-8
Source: 0000950170-25-064589
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-05-06
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on May 6, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter)

| Delaware                                                                              |     | 94-2875566                          |
| (State or other jurisdiction of incorporation or organization)                        |     | -I.R.S. Employer Identification No. |
| 100 Regency Forest Drive, Suite 300, Cary, NC(Address of Principal Executive Offices) |     | 27518(Zip Code)                     |

Non-Plan Inducement Stock Option Grant Non-Plan Inducement Performance-Vesting Stock Option Grant Non-Plan Inducement Restricted Stock Unit Grant (Full Title of the Plans) Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. 100 Regency Forest Drive, Suite 300 Cary, North Carolina 27518 (Name and address of agent for service) (858) 251-4400 (Telephone number, including area code, of agent for service) Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☒ |
| Non-accelerated filer   |     | ☐ |     | Smaller reporting company |     | ☐ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>EXPLANATORY NOTE</div>

This Registration Statement on Form S-8 is being filed to register 1,900,000 shares of common stock, par value $0.01 per share (“Common Stock”), of Heron Therapeutics,